JNJ 56914845

Drug Profile

JNJ 56914845

Alternative Names: 2336805; GSK-2336805; GSK805; JNJ-56914845

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Janssen
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 19 Aug 2015 Phase-II development is ongoing in Belgium, Bulgaria, France, Germany, Puerto Rico and USA
  • 01 Dec 2014 Janssen R&D Ireland completes a phase IIa trial in Hepatitis C (combination therapy, treatment-naive or treatment experienced) in Belgium and Germany (NCT01724086; EudraCT2012-002555-42)
  • 01 Jul 2014 GlaxoSmithKline completes a phase II trial in Hepatitis C (Combination therapy, Treatment-naive) in USA, Puerto Rico, Belgium, Bulgaria, France and Germany (NCT01648140)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top